Our findings that FSH injection reduces weight gain and improved glucose tolerance in the absence of either ovarian or supplemented estradiol highlight the potential clinical benefit of FSH receptor agonists for the treatment of metabolic syndrome and also open up the possibility of drug repurposing for FSH. This evidence concerns the gene FSHR and metabolic syndrome.